Daily Cardiology Research Analysis
Analyzed 179 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies stood out today. A Science study links severe obesity in HFpEF to reversible sarcomeric dysfunction and troponin-I Thr181 hyperphosphorylation, suggesting weight loss and sarcomere enhancers as therapeutic avenues. A JCI paper maps N-terminal ApoB domains that drive endothelial uptake of atherogenic lipoproteins and shows an ApoB18 fragment reduces atherosclerosis in mice, while a multicenter RCT in JACC shows left bundle branch pacing prevents pacing-induced cardiomyopathy versus right ventricular pacing.
Research Themes
- Obesity-driven sarcomere dysfunction in HFpEF and its reversibility
- Endothelial–lipoprotein interactions via ApoB N-terminus as therapeutic targets in atherosclerosis
- Conduction system pacing to prevent pacing-induced cardiomyopathy
Selected Articles
1. Severe obesity in human HFpEF alters contractile protein function and organization.
This mechanistic human study shows that severe obesity in HFpEF is associated with markedly depressed myocyte contractile reserve (reduced Ca2+/length-tension, power, myosin activation), correlating with BMI and exercise hemodynamics. Defects appear reversible with weight loss, and a unique increase in troponin-I Thr181 phosphorylation is implicated in sarcomere dysfunction, highlighting weight reduction and sarcomere enhancers as potential therapies.
Impact: It reframes HFpEF pathophysiology in the obesity era by pinpointing reversible sarcomeric defects and a phospho-troponin signature, opening a translational path from weight loss to sarcomere-targeted therapies.
Clinical Implications: Prioritize structured weight-loss interventions in obese HFpEF and consider clinical development of sarcomere enhancers; mechanistic biomarkers (e.g., troponin-I Thr181 phosphorylation) may inform patient phenotyping and therapeutic targeting.
Key Findings
- Cardiomyocytes from severely obese HFpEF show markedly reduced Ca2+- and length-stimulated tension, power, and myosin activation versus less-obese HFpEF and non-failing controls.
- Myocyte contractile defects correlate with BMI and exercise hemodynamics in HFpEF and appear reversible with weight loss.
- Troponin-I Thr181 phosphorylation is increased only in HF with obesity, implicating a specific sarcomeric dysfunction mechanism.
- Findings suggest therapeutic benefit from weight reduction and potential from sarcomere enhancers in obese HFpEF.
Methodological Strengths
- Mechanistic measurements in human HFpEF cardiomyocytes with comprehensive biophysical assays.
- Correlation with clinical phenotypes (BMI, exercise hemodynamics) and reversibility assessment with weight loss.
Limitations
- Exact sample size and selection criteria are not specified in the abstract, potentially limiting generalizability.
- Observational correlations and ex vivo assessments limit causal inference for clinical outcomes.
Future Directions: Validate troponin-I Thr181 phosphorylation as a biomarker; test sarcomere enhancers in obese HFpEF; conduct interventional trials of structured weight-loss programs stratified by myocyte functional phenotypes.
Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality and has few effective therapies. Its phenotype has changed over time, with morbid obesity and metabolic defects supplanting hypertension and cardiac hypertrophy. We reveal that cardiomyocytes from patients with severe obesity and HFpEF have very depressed contractile reserve, including reduced calcium- and length-stimulated tension, power, and myosin activation compared to less-obese HFpEF and non-failing (NF) controls ±obesity, but similar to advanced HF with reduced EF. Myocyte defects correlate with body mass index and exercise hemodynamics in patients with HFpEF but not NF and appear reversible upon weight loss. Increased troponin-I phosphorylation at Thr181 occurs only in HF+obesity contributing to sarcomere dysfunction. Weight reduction and sarcomere enhancers may offer benefits in HFpEF with obesity.
2. The N-terminus of Apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.
Distinct N-terminal domains of ApoB mediate endothelial uptake of atherogenic lipoproteins via SR-BI and ALK1. An 18% N-terminal fragment (ApoB18) inhibits endothelial transport of chylomicrons and LDL and reduces atherosclerosis in hypercholesterolemic mice, suggesting a receptor-blocking decoy strategy to prevent vascular lipid entry.
Impact: It pinpoints actionable ApoB–endothelium interfaces that drive arterial lipoprotein entry and demonstrates in vivo atherosclerosis reduction with a decoy fragment, charting a novel anti-atherosclerotic modality beyond lipid lowering.
Clinical Implications: Therapeutics that block ApoB N-terminus interactions (e.g., ApoB18-mimetic peptides/biologics) could complement statins/PCSK9 inhibitors by preventing endothelial lipoprotein transcytosis; biomarker-guided selection may focus on high TRL/LDL flux phenotypes.
Key Findings
- Different ApoB N-terminal regions interact with endothelial SR-BI and ALK1 to mediate chylomicron and LDL uptake.
- ApoB48 lipoproteins are internalized only via SR-BI, highlighting receptor specificity.
- ApoB18 fragment reduces endothelial uptake/transport of both chylomicrons and LDL and decreases atherosclerosis in hypercholesterolemic mice.
- A shorter fragment (ApoB12) selectively blocks ALK1-mediated uptake of ApoB100 lipoproteins.
Methodological Strengths
- Integrated molecular mapping (fragments, mutagenesis, modeling) with cell and mouse validation.
- Demonstration of in vivo atheroprotection in hypercholesterolemic mice.
Limitations
- Translational applicability of ApoB18 delivery, dosing, and long-term safety remains untested in humans.
- Abstract does not detail sample sizes or potential off-target effects of fragments.
Future Directions: Develop ApoB18-mimetics with optimized pharmacokinetics; evaluate combination with LDL-lowering agents; quantify endothelial transcytosis reduction and plaque effects in large-animal models before first-in-human studies.
Apolipoprotein B (APOB) containing lipoproteins contribute to atherosclerosis by entering the arterial wall through the endothelial cell (EC) surface receptors scavenger receptor-BI (SR-BI) and activin receptor-like kinase 1 (ALK1). We used N-terminal fragments of APOB, molecular modeling, and site-directed mutagenesis to identify and block the binding of chylomicrons and LDL to these receptors in cells and mice. We discovered that different APOB regions interact with SR-BI and ALK1 expressed on ECs APOB48 lipoproteins were only internalized by SR-BI. A fragment of APOB, comprising 18% of the N-terminal sequence, APOB18, reduced the uptake and transport of both chylomicrons and LDL by ECs, whereas a shorter fragment, APOB12, only blocked ALK1 mediated uptake of APOB100 containing lipoproteins. Importantly, overexpressing APOB18 decreased atherosclerosis in hypercholesterolemic mice. These findings identify the N-terminal region of APOB as the cause of atherosclerosis and illustrate an approach to treating or preventing vascular disease.
3. Randomized Trial of Left Bundle Branch Pacing vs Right Ventricular Pacing in Vulnerable Cardiac Function.
In a multicenter RCT of 160 high pacing burden patients at risk for dysfunction, LBBP reduced the composite of all-cause death, HF hospitalization, or PICM versus RVP (HR 0.31), primarily by lowering PICM. LBBP also improved LVEF, LV dimensions, and NYHA class over 36 months.
Impact: Provides randomized evidence that conduction system pacing prevents remodeling and PICM compared to conventional RVP, informing device strategy in high pacing burden patients.
Clinical Implications: For patients expected to have high ventricular pacing burden, consider LBBP as default to prevent PICM and adverse remodeling, with echocardiographic and symptomatic benefits over 3 years.
Key Findings
- Primary composite endpoint occurred in 11.6% (LBBP) vs 33.9% (RVP); HR 0.310 (95% CI 0.145-0.664; P=0.001).
- Reduction driven mainly by lower PICM: 6.5% vs 18.2% (sHR 0.324; P=0.028).
- Greater improvements with LBBP in LVEF (+5.34%), LVEDD (-3.06 mm), LVESD (-3.74 mm), and better NYHA class at 36 months.
Methodological Strengths
- Prospective multicenter randomized controlled design with 36-month follow-up.
- Clinically relevant composite endpoint and comprehensive echocardiographic remodeling metrics.
Limitations
- Modest sample size and no blinding; mortality and HF hospitalization components were not individually significant.
- Operator expertise and device programming may affect generalizability.
Future Directions: Larger, pragmatic trials to confirm mortality and HF hospitalization benefits; cost-effectiveness and implantation feasibility across centers; head-to-head with His-bundle pacing.
BACKGROUND: Right ventricular pacing (RVP) is associated with an increased risk of pacing-induced cardiomyopathy (PICM) in high pacing burden patients. Left bundle branch pacing (LBBP), a more physiological pacing modality, may better preserve cardiac function. OBJECTIVES: This randomized trial aimed to evaluate the clinical outcomes of LBBP versus RVP in high pacing burden patients with high risk of cardiac dysfunction. METHODS: In this prospective, multicenter, randomized controlled trial, 160 high pacing burden patients with high risk of cardiac dysfunction were randomly assigned in a 1:1 ratio to either LBBP or RVP. The primary endpoint was a composite of all-cause mortality, heart failure hospitalization (HFH), or PICM. Secondary endpoints included the individual components of the primary endpoints, echocardiographic parameters, and New York Heart Association (NYHA) functional class. RESULTS: During a median follow-up duration of 36 months, the primary endpoint occurred in 9 patients in the LBBP group and in 25 patients in the RVP group (11.6% vs. 33.9%; HR 0.310, 95% CI 0.145-0.664; P=0.001), mainly driven by PICM (6.5% vs. 18.2%; sHR 0.324, 95% CI 0.119-0.883; P=0.028). No significant differences were observed in all-cause mortality (P=0.391) and HFH (P=0.100) between two groups. LBBP showed superior improvements than RVP in left ventricular ejection fraction (LVEF) (mean difference: 5.34, 95% CI: 3.18-7.50; P <0.001), left ventricular end-diastolic diameter (LVEDD) (mean difference: -3.06, 95% CI: -4.38- -1.73; P <0.001) and left ventricular end-systolic diameter (LVESD) (mean difference: -3.74, 95% CI: -5.07- -2.41; P <0.001) from baseline to 36 months. Patients in the LBBP group also showed favored NYHA functional class compared with those in the RVP group at 36-month follow-up (1.66 ± 0.60 vs. 1.90 ± 0.56, P = 0.014). CONCLUSIONS: In high pacing burden patients with high risk of cardiac dysfunction, LBBP significantly reduced the risk of the composite outcome, driven primarily by a decreased risk of PICM, and is associated with better echocardiographic improvements and clinical function. CONDENSED ABSTRACT: This LBBP-FAVOUR randomized trial is the first multi-center, prospective, randomized controlled trials to evaluate the clinical efficacy of left bundle branch pacing (LBBP) vs right ventricular pacing (RVP) in patients with high risk of cardiac dysfunction. During a median follow-up of 36 months, LBBP significantly reduced the risk of the composite endpoint including pacing-induced cardiomyopathy (PICM), heart failure hospitalization, and all-cause mortality compared with RVP, and this benefit was mainly driven by the reduction in PICM risk. This work lays a solid foundation for future larger randomized trials in specific patient populations to further validate these findings.